75
Views
0
CrossRef citations to date
0
Altmetric
Research

Prevalence and risk factors of dry eye disease in patients treated with aromatase inhibitors for breast cancer

, , ORCID Icon, , , & show all
Pages 415-419 | Received 17 Apr 2023, Accepted 18 Jul 2023, Published online: 12 Sep 2023

References

  • Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin 2021; 71: 209–249. doi:10.3322/caac.21660.
  • Smith IE, Dowsett M, Wood AJJ. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431–2442. doi:10.1056/NEJMra023246.
  • Spelsberg H, Klueppel M, Reinhard T et al. Detection of Oestrogen receptors (ER) α and β in conjunctiva, lacrimal gland, and tarsal plates. Eye 2004; 18: 729–733. doi:10.1038/sj.eye.6701314.
  • Barabino S, Chen Y, Chauhan S et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dryeye disease. Prog Retin Eye Res 2012; 31: 271–285. doi:10.1016/j.preteyeres.2012.02.003.
  • Rocha EM, Wickham LA, da Silveira LA et al. Identification of androgen receptor protein and 5 alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 2000; 84: 76–84. doi:10.1136/bjo.84.1.76.
  • Versura P, Giannaccare G, Campos EC. Sex-steroid imbalance in females and dry eye. Curr Eye Res 2015; 40: 162–175. doi:10.3109/02713683.2014.966847.
  • Sullivan DA. Tearful relationships? Sex, hormones, the lacrimal gland, and aqueous-deficient dry eye. Ocul Surf 2004; 2: 92–123. doi:10.1016/S1542-0124(12)70147-7.
  • Craig JP, Nichols KK, Akpek EK et al. TFOS DEWS II definition and classification report. Ocul Surf 2017; 15: 276–283. doi:10.1016/j.jtos.2017.05.008.
  • Stapleton F, Alves M, Bunya VY et al. TFOS DEWS II epidemiology report. Ocul Surf 2017; 15: 334–365. doi:10.1016/j.jtos.2017.05.003.
  • Inglis H, Boyle FM, Friedlander ML et al. Dry eyes and AIs: if you don’t ask you won’t find out. Breast 2015; 24: 694–698. doi:10.1016/j.breast.2015.08.008.
  • Schiffman RM, Christianson MD, Jacobsen G et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000; 118: 615–621. doi:10.1001/archopht.118.5.615.
  • Wolffsohn JS, Arita R, Chalmers R et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 2017;15:539–574.
  • Cai Y, Wei J, Zhou J et al. Prevalence and Incidence of Dry Eye Disease in Asia: A Systematic Review and Meta-Analysis. Ophthalmic Res 2022;65:647–658.
  • Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist 2006; 11: 718–731. doi:10.1634/theoncologist.11-7-718.
  • Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology 2017; 124: S20–S26. doi:10.1016/j.ophtha.2017.05.031.
  • Suzuki T, Schirra F, Richards SM et al. Estrogen and progesterone control of gene expression in the mouse meibomian gland. Invest Ophthalmol Visual Sci 2008; 49: 1797–1808. doi:10.1167/iovs.07-1458.
  • Schaumberg DA, Buring JE, Sullivan DA et al. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286: 2114–2119. doi:10.1001/jama.286.17.2114.
  • Bicer T, Imamoglu GI, Dogan AS et al. The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer. Int Ophthalmol 2020; 40: 2077–2083. doi:10.1007/s10792-020-01384-7.
  • Chatziralli I, Sergentanis T, Zagouri F et al. Ocular surface disease in breast cancer patients using aromatase inhibitors. Breast J 2016; 22: 561–563. doi:10.1111/tbj.12633.
  • Turaka K, Nottage JM, Hammersmith KM et al. Dry eye syndrome in aromatase inhibitor users. Clin Exp Ophthalmol 2013;41:239–43.
  • Gibson E, Stapleton F, Dear R et al. Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain. Ocul Surf 2020; 18: 108–113. doi:10.1016/j.jtos.2019.10.008.
  • Ağın A, Kocabeyoglu S, YucelGencoglu A et al. The effects of systemic aromatase inhibitors on meibomian glands and corneal structure. Eye 2022; 36: 1185–1193. doi:10.1038/s41433-021-01612-z.
  • Westgaard KL, Hynne H, Amdal CD et al. Oral and ocular late effects in head and neck cancer patients treated with radiotherapy. Sci Rep 2021; 11: 4026. doi:10.1038/s41598-021-83635-w.
  • Bhandare N, Moiseenko V, Song WY et al. Severe dry eye syndrome after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2012; 82: 1501–1508. doi:10.1016/j.ijrobp.2011.05.026.
  • Kadota Y, Okisaka S, Mizukawa A et al. A case of corneal perforation and retinopathy followed by external radiotherapy for maxillary carcinoma. Folia Ophthalmol Jpn 1988; 39: 2466–2471.
  • Park SB, Kwok JB, Asher R et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol 2017; 28: 2733–2740. doi:10.1093/annonc/mdx491.
  • Chiang JCB, Goldstein D, Trinh T et al. A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. Sci Rep 2021; 11: 1786. doi:10.1038/s41598-021-81398-y.
  • Ma J, Pazo EE, Zou Z et al. Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study. Breast 2020; 53: 164–171. doi:10.1016/j.breast.2020.07.009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.